BMO Capital Markets downgraded Pfizer to market performance and told customers that the drug maker will have "significant headwind" over the next two years, with slower revenue and weaker multiple expansion.
Shares of the world have faced the worst losing streak in more than half a decade
Oil declines, as Russia signals signals, will remain high
US Securities Regulator Appeals Tesla to Appear on Model 3 Production Estimate
Despite CIC's orders, CPM refuses information on black money
Panelists Stress Need for Joint Learning on Campuses